Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2026
ASAP score predicts early HCC recurrence after complete radiological response to locoregional treatments.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Canova Lorenzo, Iavarone Massimo, Alimenti Eleonora, Bruccoleri Mariangela, Argiento Lorenzo, Perbellini Riccardo, Facchetti Floriana, Uceda Renteria Sara, D'Ambrosio Roberta, Degasperi Elisabetta, Ierardi Anna Maria, Sangiovanni Angelo, Vidali Matteo, Lampertico Pietro
Аннотация
BACKGROUND AND AIMS: The ASAP algorithm incorporating Age, Sex, Alpha-fetoprotein (AFP), and prothrombin induced by vitamin K absence/antagonist II (PIVKA-II) has been shown to predict hepatocellular carcinoma (HCC) development. Our study evaluated the prognostic value of ASAP for early HCC recurrence after complete radiological response (CR) to locoregional therapy.
METHODS: This single-center study enrolled patients with newly diagnosed HCC who achieved CR by ablation (MWTA) or chemoembolization (TACE) and available serum samples on the day of treatment. CR was evaluated by CT-scan 1 month after treatment. PIVKA-II and AFP levels were measured using Fujirebio assays. Patients were followed up every three months until recurrence, death, or last follow-up.
RESULTS: 127 patients with HCC (median age 66 years, 79 % male, 79 % with viral etiology) who achieved CR were enrolled. At time of treatment, median AFP and PIVKA-II levels were 6.6 ng/mL and 144 mAU/mL, respectively, while median ASAP score was 0.60. During follow-up, HCC recurred in 72 (56.7 %) patients (63 within 24 months, early recurrence). ASAP score was the sole independent predictor of early recurrence [HR 2.57 (95 % CI 1.50-4.40), p=0.001] and its new cutoff of 0.797 (AUC 66 %, sensitivity 57 %, specificity 75 %) outperformed other scores and biomarkers.
CONCLUSIONS: The ASAP score accurately predicted early HCC recurrence post-CR, warranting further validation.
METHODS: This single-center study enrolled patients with newly diagnosed HCC who achieved CR by ablation (MWTA) or chemoembolization (TACE) and available serum samples on the day of treatment. CR was evaluated by CT-scan 1 month after treatment. PIVKA-II and AFP levels were measured using Fujirebio assays. Patients were followed up every three months until recurrence, death, or last follow-up.
RESULTS: 127 patients with HCC (median age 66 years, 79 % male, 79 % with viral etiology) who achieved CR were enrolled. At time of treatment, median AFP and PIVKA-II levels were 6.6 ng/mL and 144 mAU/mL, respectively, while median ASAP score was 0.60. During follow-up, HCC recurred in 72 (56.7 %) patients (63 within 24 months, early recurrence). ASAP score was the sole independent predictor of early recurrence [HR 2.57 (95 % CI 1.50-4.40), p=0.001] and its new cutoff of 0.797 (AUC 66 %, sensitivity 57 %, specificity 75 %) outperformed other scores and biomarkers.
CONCLUSIONS: The ASAP score accurately predicted early HCC recurrence post-CR, warranting further validation.
Предметные рубрики MeSH
HumansMaleCarcinoma, HepatocellularFemaleLiver NeoplasmsAgedNeoplasm Recurrence, LocalProthrombinMiddle Agedalpha-FetoproteinsChemoembolization, TherapeuticProtein PrecursorsBiomarkersAlgorithmsBiomarkers, TumorPrognosisPredictive Value of TestsAged, 80 and overTomography, X-Ray ComputedAge FactorsSex Factors